KRYS
Krystal Biotech, Inc.
Biotechnology · Healthcare · United States
324.55
close · 2026-10-29
value
16
cheaper than peers16
quality
98
stronger fundamentals98
ranked against
Biotechnology (commercial)
value
quality
161 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 21.94× | 37 |
| price to book | 7.07× | 26 |
| forward P/E | 36.25× | 22 |
| EV to EBITDA | 43.73× | 22 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 49.0% | 98 |
| debt to equity | 0.7% | 95 |
| return on equity | 20.1% | 87 |
| revenue growth | 24.1% | 53 |
4 of 4 measures available
Facts
| market cap | $10B |
| free cash flow | $151.7M |
| employees | 295 |
| first trade | 2017-09-20 |
| next earnings | 2026-11-02 |
| fundamentals updated | 2026-08-07 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 6.84 | 3.00 | 0.39 | -5.49 |
| free cash flow | $188.9M | $119.2M | -$100.6M | -$153.5M |
| net income | $204.8M | $89.2M | $10.9M | -$140.0M |
| revenue | $389.1M | $290.5M | $50.7M | $0 |
| unusual items | $0 | -$37.5M | $87.5M | -$25.0M |